Combining NAD+ with Zepbound — What the Science Shows

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, a dual GLP-1 and GIP receptor agonist approved for weight loss as Zepbound, works by regulating appetite and glucose metabolism through two distinct pathways. Many patients considering or using tirzepatide ask whether adding NAD+ supplementation—which supports cellular energy production—could amplify results. The science on this combination remains limited, but understanding each compound's mechanism helps clarify the opportunity and risks.

How Tirzepatide and NAD+ Work in Cellular Metabolism

Tirzepatide binds to GLP-1 and GIP receptors, signaling the pancreas to release insulin only when blood sugar rises, while simultaneously reducing appetite signals in the brain. This dual action produces weight loss by decreasing caloric intake and improving insulin sensitivity. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for mitochondrial function, DNA repair, and energy metabolism; it declines naturally with age and metabolic stress.

Both compounds influence energy metabolism but through different routes. Tirzepatide's primary effect centers on hormonal appetite suppression and glucose control, whereas NAD+ supports the cellular machinery that generates ATP, the currency of cellular energy. Theoretically, restoring NAD+ availability could enhance the mitochondrial efficiency needed to sustain the metabolic improvements tirzepatide initiates, though direct synergy has not been established in human trials.

Clinical Evidence for NAD+ and GLP-1 Combination Therapy

To date, no large randomized controlled trials have specifically examined NAD+ boosters (such as NMN or NR) combined with GLP-1 receptor agonists like tirzepatide in humans. Most NAD+ research has focused on aging, metabolic disease, and longevity in animal models or small adult populations, typically measuring NAD+ levels and markers of mitochondrial stress rather than weight loss outcomes.

A 2022 study in Nature Metabolism showed that NAD+ precursors improved insulin sensitivity and reduced weight gain in mice fed a high-fat diet, suggesting potential metabolic benefits. However, these findings have not been replicated in human subjects receiving concurrent GLP-1 therapy. Until prospective data emerges, combining NAD+ with tirzepatide remains a personalized choice based on individual metabolic assessment rather than established clinical protocol.

Potential Benefits and Considerations When Stacking These Compounds

Patients who combine tirzepatide with NAD+ supplementation often report subjective improvements in energy, mental clarity, and sustained weight loss momentum, though these accounts are anecdotal rather than controlled observations. The theoretical benefit lies in supporting mitochondrial function while tirzepatide optimizes hormonal appetite regulation; together, they may address metabolic dysfunction at multiple levels. Some practitioners propose that NAD+ restoration could reduce the fatigue or metabolic sluggishness some patients experience early in GLP-1 treatment.

The practical considerations include cost (NAD+ precursors range from $30 to $100 monthly), potential drug interactions, and individual variation in NAD+ metabolism influenced by genetic factors like NAMPT and SIRT gene expression. PlexusDx Precision Peptide Genetic Test maps peptide-pathway variants including metabolic efficiency markers, offering insight into whether your genetic profile suggests heightened benefit from NAD+ intervention alongside tirzepatide therapy.

Safety, Drug Interactions, and When to Consult Your Provider

NAD+ precursors (NMN, NR, and urolithin A) are generally recognized as safe in doses under 1,000 mg daily and do not directly interact with tirzepatide at the receptor level. However, both compounds influence glucose metabolism and insulin sensitivity; combining them without medical oversight could theoretically lower blood glucose too rapidly in patients with prediabetes or on concurrent insulin therapy, requiring dose adjustment or closer monitoring.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Zepbound or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can I take NAD+ supplements while on tirzepatide injections?

NAD+ precursors do not directly interact with tirzepatide at the receptor level and are generally safe when used at standard doses (500–1,000 mg daily). However, both compounds affect glucose metabolism, so notify your provider before combining them to ensure your blood sugar remains stable and your tirzepatide dose does not need adjustment.

Does NAD+ actually improve weight loss results with tirzepatide?

Human clinical trials have not yet demonstrated that NAD+ boosters enhance weight loss when combined with GLP-1 agonists. While NAD+ supports mitochondrial energy production and insulin sensitivity in animal and cell studies, individual results vary greatly based on genetics, diet, exercise, and baseline metabolic health.

How much does PlexusDx tirzepatide cost, and can I add NAD+ support?

PlexusDx Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan), with your dose adjusted as needed while your price remains flat. NAD+ supplementation is separate and typically ranges from $30–$100 monthly depending on the product; PlexusDx does not currently bundle NAD+ but supports integrative conversations with your provider.

What are the side effects of combining NAD+ and tirzepatide?

Tirzepatide commonly causes mild nausea and gastrointestinal effects; NAD+ precursors may cause headaches or flushing in some users. Combining them increases the risk of rapid blood sugar drops in susceptible patients, making provider oversight essential. Most combinations are well-tolerated when doses are conservative and glucose is monitored.

Can genetic testing tell me if NAD+ supplementation will help me?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Fridays Zepbound

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.